Società | Nome | Borsa | Settore | Industria | 3 mesi | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABVC Biopharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 318,7% | 58,18 Mln USD | -7,9x | -0,23 | 3,58 USD | 1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Metaplanet | OTC Markets | 241,9% | 6,01 Mrd USD | 260,2x | 3,37 | 9,30 USD | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||||
IREN Ltd | NASDAQ | Tecnologia | Tecnologia finanziaria (fintech) e infrastrutture | 222,9% | 4,37 Mrd USD | -45,5x | 1,98 | 18,05 USD | 4,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,2% Rialzo | Fai l’upgrade a Pro+ | |
Nuscale Power | NYSE | Utenze | Utenze elettriche | 220,5% | 13,32 Mrd USD | -17x | 0,9 | 46,83 USD | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -21,9% Ribasso | Fai l’upgrade a Pro+ | |
D Wave Quantum | NYSE | Tecnologia | Software e servizi IT | 199,7% | 6,08 Mrd USD | -32,4x | 2,65 | 19,24 USD | 13,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,4% Rialzo | Fai l’upgrade a Pro+ | |
Robinhood Markets | NASDAQ | Tecnologia | Tecnologia finanziaria (fintech) e infrastrutture | 156,1% | 93,05 Mrd USD | 59x | 0,05 | 105,45 USD | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,7% Ribasso | Fai l’upgrade a Pro+ | |
Ast Spacemobile | NASDAQ | Tecnologia | Servizi di telecomunicazione | 145,6% | 19,40 Mrd USD | -31,8x | 0,46 | 57,45 USD | 9,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -13,7% Ribasso | Fai l’upgrade a Pro+ | |
Coinbase Global | NASDAQ | Tecnologia | Tecnologia finanziaria (fintech) e infrastrutture | 134,7% | 104,62 Mrd USD | 70,6x | 13,52 | 410,75 USD | 3,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -24,7% Ribasso | Fai l’upgrade a Pro+ | |
Septerna | NASDAQ | Salute | Ricerca medica e biotecnologica | 113,9% | 562,33 Mln USD | -3,2x | 0,06 | 12,62 USD | 5,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Ascentage Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 111,6% | 3,36 Mrd USD | -30,1x | -0,97 | 39,62 USD | 2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -27,5% Ribasso | Fai l’upgrade a Pro+ | |
ProQR Therapeutics NV | NASDAQ | Salute | Ricerca medica e biotecnologica | 110,5% | 252,82 Mln USD | -6,3x | 4,09 | 2,40 USD | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Phathom Pharma | NASDAQ | Salute | Prodotti farmaceutici | 106,7% | 579,47 Mln USD | -1,6x | 0,1 | 8,32 USD | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
51Talk Online Education DRC | NYSE | Servizi accademici e di formazione | Fornitori di servizi di formazione | 97,7% | 170,63 Mln USD | -37x | -0,51 | 29,12 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Argo Corp | OTC Markets | Tecnologia | Software e servizi IT | 84,7% | 66,63 Mln USD | -0,07 | 0,46 USD | 4,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Hims Hers Health | NYSE | Salute | Fornitori e servizi sanitari | 83,6% | 11,19 Mrd USD | 66,2x | 0,01 | 49,99 USD | -3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -15,1% Ribasso | Fai l’upgrade a Pro+ | |
Futu | NASDAQ | Tecnologia | Tecnologia finanziaria (fintech) e infrastrutture | 80,3% | 20,89 Mrd USD | 24,8x | 0,41 | 150,06 USD | 4,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 1,5% Rialzo | Fai l’upgrade a Pro+ | |
Critical Metals Corp | NASDAQ | Prodotti di base | Metalli e miniere | 75,1% | 451,71 Mln USD | -1x | 4,36 USD | 6,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
CureVac NV | NASDAQ | Salute | Ricerca medica e biotecnologica | 73,1% | 1,22 Mrd USD | 5,8x | 0,04 | 5,40 USD | -1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -4,8% Ribasso | Fai l’upgrade a Pro+ | |
Astera Labs | NASDAQ | Tecnologia | Semiconduttori e apparecchiature per semiconduttori | 66,1% | 16,15 Mrd USD | 280x | 3,32 | 97,95 USD | 6,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,8% Rialzo | Fai l’upgrade a Pro+ | |
Yuanbao | NASDAQ | 65,7% | 1,19 Mrd USD | 6,5x | 0,05 | 26,45 USD | 6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||||
Arrowhead Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 62,8% | 2,60 Mrd USD | -16,7x | -0,24 | 18,85 USD | 3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Abivax ADR | NASDAQ | Salute | Ricerca medica e biotecnologica | 61,6% | 641,20 Mln USD | -0,26 | 10,34 USD | 4,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Sailfish Royalty | OTC Markets | Prodotti di base | Metalli e miniere | 57,6% | 130,10 Mln USD | 167x | 0,9 | 1,81 USD | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Stoke Therapeutics | NASDAQ | Salute | Ricerca medica e biotecnologica | 54,7% | 674,27 Mln USD | 13,9x | 0,09 | 12,35 USD | 3,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Salute | Ricerca medica e biotecnologica | 52,7% | 8,38 Mrd USD | -52,7x | -1,12 | 129,46 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -0,4% Ribasso | Fai l’upgrade a Pro+ | |
Himalaya Shipping | NYSE | Industriali | Trasporto e logistica | 52,1% | 325,20 Mln USD | 20,1x | 0,14 | 6,92 USD | 3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 31,3% Rialzo | Fai l’upgrade a Pro+ | |
DeFi Tech | NASDAQ | Tecnologia | Tecnologia finanziaria (fintech) e infrastrutture | 50,5% | 1,09 Mrd USD | 55,8x | 0,39 | 3,28 USD | -3,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Gold Royalty | NYSE | Finanziario | Servizi bancari e di Investimenti | 48,5% | 412,58 Mln USD | -122,7x | -1,44 | 2,42 USD | -0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 23% Rialzo | Fai l’upgrade a Pro+ | |
NYSE | Tecnologia | Software e servizi IT | 48,2% | 26,30 Mrd USD | 232x | 2,13 | 142,52 USD | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,9% Rialzo | Fai l’upgrade a Pro+ | ||
Up Fintech | NASDAQ | Finanziario | Servizi bancari e di Investimenti | 48% | 1,75 Mrd USD | 20,8x | 0,23 | 9,92 USD | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,9% Rialzo | Fai l’upgrade a Pro+ | |
Capital Clean Energy | NASDAQ | Industriali | Trasporto e logistica | 44,9% | 1,44 Mrd USD | 41,8x | 0,97 | 24,45 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -1,8% Ribasso | Fai l’upgrade a Pro+ | |
Regenxbio Inc | NASDAQ | Salute | Ricerca medica e biotecnologica | 43,1% | 437,88 Mln USD | -2,9x | -0,06 | 8,69 USD | 2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Dominari Holdings | NASDAQ | Finanziario | Servizi bancari e di Investimenti | 40,7% | 82,23 Mln USD | -1x | 0,08 | 5,61 USD | 2,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Elron Electronic Industries | OTC Markets | Finanziario | Servizi bancari e di Investimenti | 39,6% | 81,20 Mln USD | 4,2x | 0,01 | 1,54 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Volitionrx Ltd | NYSE | Salute | Ricerca medica e biotecnologica | 38% | 69,67 Mln USD | -2,6x | -0,07 | 0,68 USD | -3,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cellectis | NASDAQ | Salute | Ricerca medica e biotecnologica | 37,2% | 130,37 Mln USD | -2,9x | -0,04 | 1,93 USD | -3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Mirum Pharmaceuticals | NASDAQ | Salute | Prodotti farmaceutici | 35% | 2,61 Mrd USD | -32,8x | -0,6 | 52,73 USD | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 37,5% Rialzo | Fai l’upgrade a Pro+ | |
Kuros Biosciences | OTC Markets | Salute | Ricerca medica e biotecnologica | 34,9% | 1,37 Mrd USD | -289,3x | -4,36 | 36,01 USD | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
NewAmsterdam Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 34,5% | 2,47 Mrd USD | -11,9x | -0,39 | 21,98 USD | 5,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
China Fund | NYSE | Finanziario | Investimenti collettivi | 32,7% | 152,86 Mln USD | 8x | 15,30 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Avadel Pharma | NASDAQ | Salute | Prodotti farmaceutici | 32,6% | 1,05 Mrd USD | -36,6x | -0,46 | 10,84 USD | 1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 47,6% Rialzo | Fai l’upgrade a Pro+ | |
Financial 15 | OTC Markets | Finanziario | Investimenti collettivi | 32,3% | 446,12 Mln USD | 1,7x | 7,16 USD | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Tetragon | OTC Markets | Finanziario | Investimenti collettivi | 30,9% | 1,41 Mrd USD | 4,2x | 17,20 USD | 4,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Ares Commercial RE | NYSE | Immobiliare | REIT residenziali e commerciali | 30,1% | 247,98 Mln USD | -18,6x | -0,27 | 4,51 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,9% Rialzo | Fai l’upgrade a Pro+ | |
Centessa Pharmaceuticals | NASDAQ | Salute | Ricerca medica e biotecnologica | 29,8% | 2,13 Mrd USD | -7,3x | 0,33 | 15,96 USD | 2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Finance of America Companies | NYSE | Finanziario | Servizi bancari e di Investimenti | 25,9% | 589,24 Mln USD | 4,3x | 0,04 | 24,27 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,6% Rialzo | Fai l’upgrade a Pro+ | |
BeOne Medicines DRC | NASDAQ | Salute | Ricerca medica e biotecnologica | 25,7% | 34,39 Mrd USD | -68,1x | -1,65 | 290,35 USD | 4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,6% Rialzo | Fai l’upgrade a Pro+ | |
XOMA | NASDAQ | Consumi ciclici | Media e pubblicazioni | 25,6% | 314,73 Mln USD | -36,1x | -0,45 | 26,30 USD | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Canadian General Investments | OTC Markets | Finanziario | Investimenti collettivi | 24,9% | 621,88 Mln USD | 2,8x | 29,41 USD | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
SANUWAVE | NASDAQ | Salute | Attrezzature e forniture medicali | 24,8% | 320,01 Mln USD | -6,6x | -0,49 | 37,42 USD | 6,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |